Ashley Fraser and Clara Zacharko, CRA Life Sciences Practice, Toronto look at what revised guidelines to the Patented Medicine Prices Review Board means for drug pricing in Canada.
After multiple delays, the PMPRB (Patented Medicine Prices Review Board) is expected to implement revised guidelines as of January 1, 2022, which include an update to the reference basket of international price comparator countries. These changes are likely to drive a significant reduction in the list price ceiling for new medicines launching in Canada, affecting existing pricing and access decision-making processes and decreasing manufacturer willingness to invest in the Canadian market.
PMPRB: overview of key changes